13F Holdings
中文EN

STTK Shattuck Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680367 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-66.6%
TTM net income YoY14.5%
TTM EPS YoY63.6%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,578.7%
Net margin-5,256.8%
FCF margin—
EBITDA margin-5,221.0%

Returns

ROE-39.2%
ROA-36.9%
ROIC (approx.)-57.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets4.3%
Debt / equity0.00x
Current ratio27.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.00M$5.72M$1.66M$652,000$30.02M
R&D expense$35.27M$67.21M$74.31M$82.90M$56.56M
SG&A expense$17.23M$19.08M$19.30M$21.08M$18.72M
Operating income-$51.51M-$80.57M-$91.96M-$103.33M-$45.27M
Income tax$0$0$0$0$0
Net income-$48.81M-$75.41M-$87.30M-$101.94M-$44.97M
EBITDA-$47.81M-$76.77M-$87.96M-$100.23M-$43.87M
EPS (basic)-0.70-1.49-2.05-2.41-1.07
EPS (diluted)-0.70-1.49-2.05-2.41-1.07
Weighted avg. shares (diluted)69.58M50.76M42.60M42.38M42.03M
Balance sheet
Cash & equivalents$54.19M$57.39M$125.63M$47.38M$92.27M
Short-term investments——$5.00M$113.90M$176.54M
Current assets$82.47M$79.22M$143.22M$184.58M$288.27M
PP&E, net$6.11M$9.81M$13.80M$17.67M$9.94M
Total assets$91.03M$91.05M$159.56M$205.32M$298.58M
Current liabilities$7.05M$8.92M$11.45M$24.96M$24.59M
Total liabilities$8.64M$11.42M$14.86M$29.17M$26.80M
Shareholders' equity$82.39M$79.63M$144.71M$176.16M$271.79M
Shares outstanding63.28M47.71M47.26M42.39M42.34M
Cash flow statement
Operating cash flow-$39.88M-$60.52M-$81.23M-$94.50M-$57.12M
Capital expenditure$71,000$59,000$407,000$11.61M$7.93M
Free cash flow-$39.95M-$60.57M-$81.64M-$106.11M-$65.04M
Investing cash flow-$7.89M-$8.51M$110.86M$49.44M-$10.44M
Financing cash flow$44.57M$787,000$48.62M$171,000$1.93M
Depreciation & amortization$3.70M$3.80M$4.00M$3.10M$1.40M
Stock-based compensation$7.00M$9.55M$6.94M$6.46M$5.47M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.